MX-MAP: Towards MXenes’ biomedical applications by high-dimensional immune MAPping
Project details
Total cost:
EUR 1 389 200EU contribution:
EUR 1 389 200Coordinated in:
ItalyTopic(s):
MSCA-RISE-2021 - Marie Skłodowska-Curie Research and Innovation Staff Exchange (RISE)Call for proposal:
HORIZON-MSCA-2021-SE-01Funding scheme:
MSCA-RISE - Marie Skłodowska-Curie Research and Innovation Staff Exchange (RISE)General description and objective
Innovative biomedical applications of MXenes nanomaterials MXenes are a new family of recently discovered 2D transition metal carbides, carbonitrides, and nitrides. The immune characterisation of the new materials on the basis of their physical-chemical and immunological properties will open up perspectives for the development of new therapeutic applications of nanomaterials in tissue engineering, cancer therapy, as antibacterial agents, and as immunomodulators. Funded by the Marie Skłodowska-Curie Actions programme, the MX-MAP project will develop key strategies for MXene medical applications. The long-term goal of MX-MAP is to create a pipeline using new MXene nanomaterials for the qualitative and quantitative assessment of immunological compatibility in biomedical applications. This international research/training programme aims to support the career development of young researchers with an interdisciplinary vision of science.
The long-term goal of MX-MAP is to develop a functional pipeline for the immune characterization of new 2D nanomaterials of MXene family, for the qualitative and quantitative assessment of the human immune compatibility and immune activity towards biomedical applications. The immune characterization of the tested materials on the basis of intrinsic physical-chemical and immunological properties, through the combination of the most innovative technologies such as single-cell mass cytometry (CyTOF), will open breakthrough perspectives for the development of new therapeutic approaches applying nanomaterials as immunomodulators, scaffolds for tissue engineering, cancer therapy, and antibacterial agents.
MX-MAP will develop key chemistry and immune-based strategies for MXene medical applications. The implication of this project extends beyond the specific nanoscience program greatly advancing the engineering process of 2D materials and their use in biomedicine.
The MX-MAP project involves fourteen key players in European and non-European countries, including the United States, Canada, Saudi Arabia, and three partners from Ukraine, coming from academia and SMEs. This program will provide strong support for the development of the careers of young brilliant scientists who want to grow towards an interdisciplinary vision of Science. Chemistry, biology, immunology, engineering, and cancer research are the expertise of MX-MAP. The senior team members are among the most influential scientists, including Prof. Yury Gogotsi (H-index=168) - inventor of MXenes, Prof. Klaus Ley (H-index=147) - one of the most cited immunologists worldwide, and Prof. Husam N Alshareef (H-index=99). The Consortium is perfectly balanced in terms of equal gender presence; the project Coordinator Lucia Gemma Delogu is a female, and 2 out 4 of four WP leaders are female. The project embraces a large view of inclusiveness and diversity, including countries with smaller economies such as Ukraine.
Coordinator
UNIVERSITA DEGLI STUDI DI PADOVA
Via 8 febbraio 2, 35122 Padova, Italy
Recent news about MX-MAP project implementation:
Elucidation of Potential Genotoxicity of MXenes Using a DNA Comet Assay
Congratulations to all collaborators with this interesting joint work supported by MX-MAP project!
MXenes are among the most diverse and prominent 2D materials. They are being explored in almost every field of science and technology, including biomedicine. Despite their proven biocompatibility and low cytotoxicity, their genotoxicity has not been addressed, so we investigated whether MXenes interfere with DNA integrity in cultured cells and examined the fragmentation of their chromosomal DNA by a DNA comet assay.
| MX-MAP Session at YUCOMAT Conference 2023 "Towards MXenes’ biomedical applications by high-dimensional immune MAPping", HORIZON-MSCA-2021-SE-01 project MX-MAP. |
|
|
MX-MAP Session was held during the YUCOMAT Conference 2023 titled: "Towards MXenes’ biomedical applications by high-dimensional immune MAPping", HORIZON-MSCA-2021-SE-01 project MX-MAP.
| Launching HORIZON-MSCA-2021-SE-01 MX-MAP Project: Towards MXenes biomedical applications by high-dimensional immune MAPping |
|
|
Meeting during the MXene international conference held in Drexel University on Aug. 3, 2022, and discussing the roadmap for launching MX-MAP research project on MXenes for medical applications.
Congratulations and thank you to our collaborators from TU Wien and CEST for very interesting work and making it published! In this work, an upscalable electrochemical MXene synthesis is presented. Yields of up to 60% electrochemical MXene (EC-MXene) with no byproducts from a single exfoliation cycle are achieved.
Thank you to our collaborators for the amazing joint work recently published in Graphene and 2D Nanomaterials about MXene–silk fibroin composite films aiming to develop materials with tunable electronic and thermal properties
Dr. Oleksiy Gogotsi, director of MRC and Carbon-Ukraine, innovative companies that are among the leaders on the world MXene market, visited 2024 MRS Fall Meeting & Exhibit. together with Dr. Maksym Pogorielov, Head of Advanced Biomaterials and Biophysics Laboratory, University of Latvia.
MRC and Carbon-Ukraine team visited the 3rd International MXene conference held at Drexel University on August 5-8, 2024. Conference brought together the best reserchers and leading experts on MXene field. 
Together with colleagues from the University of Latvia, MRC/Carbone Ukraine, Adam Mickiewicz University, University Clinic Essen, and others, we have developed a novel concept involving the binding of antibodies to MXenes. In our research, we utilized anti-CEACAM1 antibodies to develop targeted photo-thermal therapy for melanoma (in vitro), paving the way for future in vivo studies and clinical trials. For the first time, we demonstrate the feasibility of delivering MXenes specifically targeted to melanoma cells, enabling the effective ablation of cancer cells under near-infrared (NIR) light. This new technique opens up vast potential for the application of MXenes in cancer treatment, diagnostics, drug delivery, and many other medical purposes.
Here we demonstrate a new developed method for depositing Ti3C2Tx MXenes onto hydrophobic electrospun PCL membranes using oxygen plasma treatment. These novel patches hold tremendous potential for providing mechanical support to damaged heart tissue and enabling electrical signal transmission,thereby mimicking the crucial electroconductivity required for normal cardiac function. After a detailed investigation of scaffold-to-cell interplay, including electrical stimulation, novel technology has the potential for clinical application not only for cardiac regeneration, but also as neural and muscular tissue substitutes.
MX-MAP project participants from MRC Dr. Oleksiy Gogotsi and Veronika Zahorodna performed split secondment visit to project partner organization University of Padova (Italy). MX-MAP project works on development of the key strategies for MXene medical applications. 
CanbioSe Project Meeting and Project Workshop was held at European Institute of Membranes (IEM), University of Montpellier, France on September 26-27, 2023. The workshop was focused on the theme of "Commercializing Biosensors, Intellectual Property, and Knowledge Transfer from Academia to Industry.
Dr. Oleksiy Gogotsi and Veronika Zahorodna visited IEEE NAP 2023 conference held in Bratislava on September 10-15, 2023. The prime focus of the IEEE NAP-2023 was on nanoscale materials with emphasis on interdisciplinary research exploring and exploiting their unique physical and chemical proprieties for practical applications.
Director of MRC and Carbon-Ukraine Dr. Oleksiy Gogotsi visited CEST labs in Wiener Neustadt (Low Energy Ion Scattering, Batteries development) and TU Vienna (ELSA, SFA). He meet with Dr. Pierluigi Bilotto, Dr. Chriatian Pichler and their colleagues, discussing novel materials and r&d activities for new technologies.